Nevro Names Kevin Thornal As Its New CEO; Investors Remain Disappointed In Results
Executive Summary
Thornal will replace Keith Grossman who is retiring. Investors and analysts hope Thornal will help the spinal cord stimulation company reach profitability by growing its “core” chronic pain business.
You may also be interested in...
JPM 2024: 'It's Really Around Focus.' Nevro Announces Restructuring Including 5% Staff Cut
Nevro will lay off 63 people to save at least $14m a year. Most of those savings will be reinvested to cover increases in normal operating costs, merit pay increases and other expenses related to the recent acquisition of Vyrsa.
News We’re Watching: Activist Investor Causes Kerfuffle At Nevro, Lifespin Launches Antibiotic Dx, And More
Medtech Insight's News We're Watching highlights medtech industry news developments that you may have missed over the last few weeks. Last week, EndoQuest closed a $42m round to support its endoluminal surgery system, Intuitive Ventures closed a $150m round, Noah Surgical announced the first biopsy procedures with its Galaxy technology in Asia, the FDA cleared Smileyscope's VR system to reduce needle anxiety, and Guardant will collaborate with Cancer Research UK.
“We’re A Pain-Management Company.” Nevro Adds SI Joint Surgery To SCS Business
Nevro is known for its spinal cord stimulation technology but wants to help a wide range of patients with chronic pain, so it is buying Vyrsa, which offers a complete system for sacroiliac joint fusion. In and interview with Medtech Insight, Nevro CEO Kevin Thornal explained how Vyrsa supports Nevro's strategy in this growing market.